Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1152/physiol.00010.2021 http://scihub22266oqcxt.onion/10.1152/physiol.00010.2021 34486395!8742736!34486395     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34486395&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Physiology+(Bethesda) 2022 ; 37 (1): 46-52 Nephropedia Template TP {{tp|p=34486395|t=2022. Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients |pdf=|usr=}}{{34486395}} gab.com Text Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients JO: Physiology (Bethesda) http://www.kidney.de/pget.php?&tw=1&pmid=34486395 #FOAvip The hypoxia-hypoxia-inducible factor (HIF)-1alpha-A2-adenosinergic pathway protects tissues from inflammatory damage during antipathogen immune responses. The elimination of this physiological tissue-protecting mechanism by supplemental oxygenation may contribute to the high mortality of oxygen-ventilated COVID-19 patients by exacerbating inflammatory lung damage. Restoration of this pathway with hypoxia-adenosinergic drugs may improve outcomes in these patients. Twit Text FOAVip Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients ????Physiology (Bethesda) http://www.kidney.de/pget.php?&tw=1&pmid=34486395 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34486395 #FOAvip English Wikipedia <ref>{{Cite pmid|34486395}}</ref> Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients #MMPMID34486395 Halpin-Veszeleiova K; Hatfield SM Physiology (Bethesda) 2022[Jan]; 37 (1): 46-52 PMID34486395show ga The hypoxia-hypoxia-inducible factor (HIF)-1alpha-A2-adenosinergic pathway protects tissues from inflammatory damage during antipathogen immune responses. The elimination of this physiological tissue-protecting mechanism by supplemental oxygenation may contribute to the high mortality of oxygen-ventilated COVID-19 patients by exacerbating inflammatory lung damage. Restoration of this pathway with hypoxia-adenosinergic drugs may improve outcomes in these patients. |*COVID-19[MESH] |*Neoplasms[MESH] |Humans[MESH] |Hypoxia[MESH] |Receptor, Adenosine A2A[MESH]Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing